Fortrea (FTRE) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fortrea (FTRE) has outperformed Exagen (XGN) over the past year, gaining 101.1% versus a loss of 25.6%. Fortrea is the larger company by market cap ($1.94 billion vs $197.9 million), about 9.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTRE | XGN |
|---|---|---|
| Share price | $20.37 | $8.17 |
| Market cap | $1.94B | $197.92M |
| 1-day change | -0.92% | -1.57% |
| YTD return | +18.09% | +34.38% |
| 1-year return | +101.09% | -25.59% |
| 5-year return | — | -35.31% |
| Forward P/E | 17.79 | — |
| EPS (TTM) | $-0.91 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.72B | — |
| Revenue growth (YoY) | +1.00% | — |
| Net income (latest FY) | $-986.20M | — |
| Gross margin | 18.50% | — |
| Operating margin | -32.04% | — |
| Net margin | -36.21% | — |
| 52-week high | $23.51 | $12.23 |
| 52-week low | $8.55 | $2.59 |
| Distance from 52-week high | -13.36% | -33.20% |
| Analyst consensus | buy | none |
| Avg. price target upside | +2.26% | +24.11% |
| Average volume | 1.49M | 328.42K |
| Shares outstanding | 95.10M | 24.23M |
| Employees | 14,000 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Fortrea is about 9.8 times larger than Exagen by market value ($1.94B vs $197.92M).
- FTRE has outperformed XGN by 126.7 percentage points over the past year.
About Fortrea
FTRE stock →Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Health Care · Medical Specialities · 14,000 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
FTRE vs XGN FAQ
Which is bigger, Fortrea or Exagen?
Fortrea (FTRE) is larger, with a market capitalization of $1.94B compared with $197.92M for Exagen (XGN).
Which stock has performed better over the past year, FTRE or XGN?
FTRE returned +101.09% over the past 12 months, compared with -25.59% for XGN (price return, excluding dividends). Past performance does not predict future results.
Are Fortrea and Exagen in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.